Many people experience a positive pregnancy test after embryo transfer, but subsequent hCG levels decline and no gestational sac is visible on ultrasound. This is commonly referred to as a “biochemical pregnancy.” This article explains what biochemical pregnancy means in IVF, breaks down the clinical process and causes, and provides key points for follow-up and preparing for another pregnancy.

I. Definition: What Exactly Is a “Biochemical Pregnancy”?

In assisted reproductive technology, “biochemical pregnancy” typically refers to a situation where pregnancy is indicated solely by urine/blood β-hCG tests, but subsequent ultrasounds consistently fail to detect a gestational sac or confirm the pregnancy location, and hCG levels decline rapidly, resulting in pregnancy termination at a very early stage.

In international reproductive medicine terminology, biochemical pregnancy is described as “a pregnancy diagnosed solely by β-hCG testing.”

In IVF contexts, one commonly used operational definition is: a positive hCG level >5 IU/L at a time point related to embryo transfer, but no gestational sac is ever visualized.

Common Misconceptions to Clarify

Biochemical pregnancy ≠ “false positive.” In most cases, it indicates that implantation occurred or was briefly established, but terminated very early.

Biochemical pregnancy ≠ ectopic pregnancy. Ectopic pregnancy may also present with abnormal hCG rise/fall and temporary absence of a gestational sac on ultrasound. However, it follows distinct follow-up protocols and carries different risk factors; it cannot be conflated with “biochemical” pregnancy.

Expert Note (Quote Box): The key to biochemical pregnancy is not “whether conception occurred,” but rather “pregnancy termination at an extremely early stage before imaging can confirm a gestational sac.” Therefore, monitoring hCG trends and ruling out ectopic pregnancy when necessary are more important than fixating on single test values.

II. Population: Which Situations Are More Prone to “Biochemical”? (Common Clinical Dimensions)

Biochemical pregnancy is part of early pregnancy outcomes and occurs beyond IVF. For IVF patients, clinicians often assess risk through the following dimensions (emphasizing “association,” not causation):

Populations with higher risk of embryonic chromosomal abnormalities

As age increases and egg quality declines, the probability of embryonic chromosomal aneuploidy rises, along with the risk of early developmental arrest. The ASRM notes in its recurrent miscarriage guidelines: Most spontaneous miscarriages before 10 weeks are associated with embryonic chromosomal number abnormalities.

Individuals with a history of recurrent early pregnancy loss or repeated implantation failure

This group requires more systematic evaluation: uterine cavity environment, immune/coagulation-related issues, endocrine metabolism (e.g., thyroid, glucose metabolism), etc. However, the need for in-depth testing depends on the number of occurrences, age, and past history.

Individuals using different transfer strategies (fresh/frozen embryos, etc.)

Biochemical pregnancy rates vary significantly across studies and populations. One comparative study reported that in IVF pregnancies involving both fresh and frozen embryos, biochemical pregnancies accounted for approximately 13.8% of all pregnancies.

Note: This figure aids understanding of “not uncommon,” but variations in center protocols, testing timepoints, and population composition cause fluctuations in rates and cannot be directly applied to individuals.

Differences in embryo development speed/transfer stage

Recent studies have explored the association between blastocyst development speed (e.g., D5 vs. D6) and biochemical risk, but these represent statistical risk indicators. Clinical decisions should still be made based on individual circumstances.

III. Technology: What Do the “Numerical Changes” You See Actually Mean?

The diagnosis of biochemical pregnancy heavily relies on the dynamic trend of β-hCG levels and the timing of ultrasound examinations.

1) β-hCG: Focusing on the “Trend” is More Critical than a “Single Point”

During early pregnancy, hCG typically shows an upward trend. If growth is significantly insufficient, plateaus, or begins to decline, it suggests the pregnancy may not continue.

Interpretation must account for medication history and specific days post-transfer due to varying testing timepoints (D3 embryos, blastocysts; presence/absence of hCG trigger/luteal support protocols).

Below is a “Follow-up Interpretation Guide” (not diagnostic thresholds, intended solely for understanding clinical reasoning):

Follow-up Point    Common Focus    Potential Next Steps

Initial Positive hCG Test    Alignment with transfer day, presence of exogenous hCG interference    Re-check trend after 48 hours

Re-check 48–72 hours    Rising, plateauing, or declining    Decide to continue/adjust luteal support

Subsequent Re-check + Ultrasound    Presence of gestational sac/yolk sac/embryo; exclusion of ectopic pregnancy    Manage as “Pregnancy Location Undetermined (PUL)” if necessary

2) Ultrasound: Timing is critical

In very early stages, failure to visualize a gestational sac is common. If hCG levels indicate a stage where visualization should occur but the sac remains “empty,” combined with hCG trends, this strongly supports “chemical pregnancy/early loss.”

ESHRE and other consensus documents emphasize that terminology for early pregnancy loss should align with clinical and imaging findings.

Expert Note (Quote Box): A single “no gestational sac seen on ultrasound” cannot directly confirm a diagnosis. Combining “hCG trend + ultrasound timing + symptoms (bleeding/abdominal pain)” provides a more accurate clinical decision.

IV. Q&A: Clarifying 6 Common Post-Transfer Questions

Q1: Does biochemical pregnancy count as “ever been pregnant”? Will it affect future cycles?

A: Medically, biochemical pregnancy is classified as “pregnancy confirmed by hCG.” However, it terminates very early and typically does not affect the feasibility of subsequent transfers or ovarian stimulation. Whether additional testing is needed depends on cycle frequency, age, and medical history.

Q2: What are the main causes of biochemical pregnancy?

A: Common clinical causes include: embryonic chromosomal abnormalities (a major cause of early loss), endometrial receptivity and synchronization issues, insufficient or mismatched luteal support, and immune/coagulation and endocrine metabolic factors. The American Society for Reproductive Medicine (ASRM) provides clear guidance on the significance of chromosomal abnormalities in early miscarriages.

Q3: Does bleeding always indicate a biochemical pregnancy?

A: Not necessarily. Light bleeding after transfer may relate to cervical/vaginal changes, medication effects, or implantation-related alterations; it could also signal threatened miscarriage or ectopic pregnancy risk. A biochemical pregnancy is confirmed only by hCG levels and ultrasound follow-up.

Q4: Do I need hysteroscopy/immunological testing after a biochemical pregnancy?

A: A single biochemical pregnancy typically does not necessitate a comprehensive screening battery. However, if recurrent biochemical pregnancies/early losses occur, or if there are significant menstrual irregularities, recurrent endometrial issues, or a family/personal history of thrombosis, then tiered testing under medical evaluation is more appropriate.

Q5: Can PGT-A (embryo chromosomal screening) prevent biochemical pregnancies?

A: PGT-A helps select chromosomally normal (euploid) embryos, potentially reducing early loss risks caused by aneuploidy. However, it does not cover all causes and does not guarantee a live birth. (Clinical applicability depends on medical indications and center protocols.)

Q6: How long after biochemical pregnancy can I resume embryo transfer/trying again?

A: Typically, wait until hCG levels return to negative or near baseline, bleeding stops, and the doctor assesses uterine and endometrial recovery before scheduling. Specific intervals depend on whether protocol adjustments are needed (natural vs. artificial cycles, luteal support methods).

V. Standard Pathway: From “Biochemical Pregnancy Detection” to “Next More Stable Cycle”

Below is a clinically oriented “decision flowchart” (may vary by hospital):

Confirmation: hCG Trend Reassessment

Reassess within 48–72 hours to determine if the rise aligns with expectations or if a decline has begun.

Risk Exclusion: Manage per PUL/Ectopic Pregnancy Protocol if necessary

If hCG is abnormal and accompanied by abdominal pain, increased bleeding, or if the physician deems risk present, more frequent follow-ups and ultrasounds will be scheduled. ESHRE consensus guidelines emphasize consistent terminology and management for “non-visual pregnancy loss/PUL.”

Management: Adjust luteal support/discontinue medication under physician guidance

Not all patients require immediate discontinuation; nor do all require continuation. The key depends on trend assessment and risk evaluation.

Review: Identify “Most Likely Factors”

Embryo-related: Embryo stage, grade, prior fertilization/development history, consideration for genetic testing

Endometrial-related: Endometrial thickness/morphology, transfer window, presence of polyps/adhesions/chronic endometritis clues

Systemic-related: Thyroid function, glucose metabolism, weight management, vitamin D, lifestyle factors (select based on indications)

Developing the Next Cycle Strategy

Potential Adjustments: Timing of transfer, endometrial preparation protocol, luteal support approach, consideration of more comprehensive uterine cavity evaluation, etc.

Expert Note (Quote Box): A biochemical pregnancy is more akin to a signal indicating “early-stage mismatch.” Review should prioritize verifiable, modifiable factors (follow-up protocols, endometrial preparation, luteal support, basal metabolism/thyroid function, etc.), avoiding excessive testing or medication based on a single outcome.

VI. Summary Box: Key Takeaways in One Sentence

What does biochemical pregnancy mean in IVF? — Refers to an extremely early pregnancy termination where hCG indicates pregnancy but no gestational sac is visible on ultrasound, with hCG levels rapidly declining.

Biochemical pregnancies are not uncommon; studies show their incidence in IVF pregnancies can fluctuate above 10% (influenced by population and criteria).

Key assessment: Monitor hCG trends + timely ultrasound; rule out PUL/ectopic pregnancy if necessary.

Next steps: Most individuals can proceed with subsequent treatments after standardized follow-up; need for further investigation depends on recurrence, age, and history (tiered management is advisable).

For fertility consultation in Kyrgyzstan, please contact your dedicated consultant

/Fertility Consultation /

Dr.Chan

Copy and add: Tulip_EnoChan

Or long press/scan the QR code to add

Tulip International Fertility Center

Technology aids fertility, fulfilling dreams for countless families